VEGFB and myeloid sarcoma: In this regard, our results have shown that subjects with high VEGFb levels at baseline (over the 75th percentile of the variable), have lower probabilities of developing MS, compared with those with lower VEGFb levels, independently of the age, sex and baseline fasting glucose level, waist circumference, serum lipids, blood pressure, inflammatory state or physical activity level.